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Abstract
TET2, a member of the ten-eleven-translocation (TET) family genes that modify DNA by converting
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), is located in chromosome 4q24 and is
frequently mutated in myeloid malignancies. The impact of TET2 mutation on survival outcomes is still
controversial; however, functional studies have proved that it is a loss-of-function mutation that impairs
myeloid cell differentiation and contributes to the phenotype of myeloid neoplasia. We, herein, aimed to
investigate TET2 expression in patients with myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML). A significantly decreased TET2 expression was observed in bone marrow cells from AML
(n = 53) and patients with MDS (n = 64), compared to normal donors (n = 22). In MDS, TET2 expression
was significantly reduced in RAEB-1/RAEB-2 compared to other WHO 2008 classifications, and a lower
TET2 expression was observed at the time of MDS disease progression in four of five patients. In
multivariate analysis, low TET2 expression (P = 0.03), male gender (P = 0.02), and WHO 2008
classification (P < 0.0001) were independent predictors of poorer overall survival. These results suggest
that defective TET2 expression plays a role in the MDS pathophysiology and predicts survival outcomes in
this disease.
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The gene encoding the methyl cytosine dioxygenase ten-ele-
ven-translocation 2 (TET2) has been found to be mutated in
a significant proportion of patients with myeloid malignan-
cies, including myelodysplastic syndromes (MDS), acute
myeloid leukemia (AML), myeloproliferative neoplasms
(MPN), and especially in chronic myeloid monocytic leuke-
mia (CMML) (1–3). TET2 alterations are loss-of-function
mutations due to single copy defects, double copy defects, or
nonsense/frameshift mutations; however, mutations are mainly
heterozygous, which strongly suggests that this is a tumor
suppressor gene implicated in the myeloid malignancies, and
TET2 haploinsufficiency may be sufficient to confer myeloid
transformation (2,4,5).
Although the impact of TET2 mutations in survival of mye-
loid malignancies is still controversial (2,6–8), the role of
TET2 in hematologic neoplasms has been well defined.
Studies using human hematopoietic stem cells (HSC) (4)
and mice models (5) have shown that TET2 loss deregulates
HSC and contributes to myeloid transformation. Ko and col-
leagues demonstrated that TET2 disruption affects 5-hmC
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levels in human myeloid cells and depletion of Tet2 in
mouse hematopoietic precursors skewed their differentiation
toward monocyte/macrophage lineages (9). CD34+ cells
from two TET2-mutated patients with MPN/MDS exhibited
enhanced repopulation capacities, compared with TET2
wild-type patients in a NOD/SCID murine model (1). Condi-
tional Tet2 loss in the hematopoietic compartment in mice
led to increased stem cell self-renewal in vivo and to a pro-
gressive enlargement of the hematopoietic stem cell compart-
ment and myeloproliferation in vivo (4). Experiments using
Tet2+/ mice demonstrated that the heterozygous cells
behaved in a similar fashion to Tet2/ cells, with serial re-
plating potential and expansion of myeloid lineage cells,
extensive infiltration of erythroblasts or myeloid cells, and a
severely skewed erythroid/myeloid ratio (5). Knockdown of
TET2 in human CD34+ cells skewed progenitor differentia-
tion toward the granulomonocytic lineage, with the advan-
tage of monocytic development, at the expense of lymphoid
and erythroid lineages (10).
In line with previous evidence that TET2 haploinsufficien-
cy may be sufficient to confer myeloid transformation and
that HSCs silenced for TET2 have impaired hematopoietic
cell differentiation, we aimed to investigate TET2 mRNA
expression in a cohort of patients with MDS and AML.
Materials and methods
Bone marrow samples
Twenty-two healthy donors and 117 patients with diagnosis
of de novo MDS (n = 64) and AML (n = 53) were included
in the study. Patients were untreated at the time of sample
collection, and patients’ characteristics are described in
Table 1. Myelodysplastic syndrome/myeloproliferative neo-
plasm and acute promyelocytic leukemia diagnoses were not
included in the study. All healthy controls and patients pro-
vided their informed written consent, and the study was
approved by the ethics committee of the institution. Patients
that attended the clinic between 2005 and 2014 and signed
their consent were included. For the purpose of this study,
the cytogenetic risk for MDS was defined according to
IPSS-R (11), and cytogenetic risk for AML was defined
according to Grimwade et al. (12). Patients were classified
according to WHO 2008 classification (13) and IPSS-R (11).
Quantitative polymerase chain reaction
Total RNA was extracted from cells using the TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). The reverse tran-
scription reaction was performed using RevertAidTM First
Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot,
Germany). Expression of TET2 mRNA was detected by
Maxima Sybr green qPCR master mix (MBI Fermentas, St.
Leon-Rot, Germany) in the ABI 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) using
specific primers: forward 50- ACGCAAGCCAGGCTAA
ACA-30, reverse 50-GCTGGGACTGCTGCATGA-30; HPRT
was used as endogenous control: forward 50-GAACGTCTT
GCTCGAGATGTGA-30, reverse 50-TCCAGCAGGTCAGC
AAAGAAT-30. The relative quantification value was
calculated using the equation, 2DDCT (14). A negative ‘No
Template Control’ was included for each primer pair. The
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MDS, myelodysplastic syndromes; WHO, World Health Organization;
RA, refractory anemia; RARS, refractory anemia with ringed sidero-
blasts; del(5q), MDS with isolated del(5q); RCMD, refractory cytope-
nia with multilineage dysplasia; RAEB-1, refractory anemia with
excess blast-1; RAEB-2, refractory anemia with excess blast-2; BM,
bone marrow; IPSS-R, Revised International Prognostic Scoring Sys-
tem; AML, acute myeloid leukemia.
aIn MDS cohort, karyotype findings included very low risk: Y (n = 1),
del(11q) (n = 1); low risk: normal (n = 49), del(5q) (n = 1); intermedi-
ate risk: +8 (n = 1), 7 (n = 1), other (n = 5); high risk: three abnor-
malities (n = 1); and very high risk: >3 abnormalities (n = 1).
bIn AML cohort, low risk karyotype included t(8;21) (n = 3) and inv(16)
(n = 1), intermediate risk included normal (n = 21), trisomy 8 (n = 4)
and other abnormalities (n = 4), and high risk included complex karyo-
type (n = 6), del(5q) (n = 2) and 7 (n = 3).
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dissociation protocol was performed at the end of each run
to check for non-specific amplification. Three replicas were
run on the same plate for each sample.
Statistical analysis
Statistical analyses were performed using GraphPad Instat 5
(GraphPad Software, Inc., San. Diego, CA, USA) or SAS
System for windows 9.2 (SAS Institute, Inc., Cary, NC,
USA). For comparisons, Fisher’s exact test was used for
categorical factors with 2 levels; the Mann–Whitney test was
used for measured factors. Cox regression model was used
to estimate overall survival (OS) and event-free survival
(EFS) for patients with MDS. The stepwise process of selec-
tion was used for multivariate analysis. OS was defined from
the time of sampling to date of death or last follow-up, and
EFS was defined as the time of sampling to the date of pro-
gression to high-risk MDS or AML with myelodysplasia-
related changes, date of death or last follow-up. A P value
<0.05 was considered as statistically significant.
Results
TET2 expression is downregulated in bone marrow
cells from patients with high-risk MDS and AML
TET2 transcripts were significantly reduced in total bone
marrow cells from patients with MDS and AML compared
with cells from healthy donors [MDS: median 0.63 (range
0.01–10.54), and AML: 0.52 (0.01–32.69) vs. healthy
donors: 2.72 (0.43–31.49), P < 0.0001]; (Fig. 1A). Patients
with MDS classified as refractory anemia with excess blast-1
(RAEB-1) and refractory anemia with excess blast-2
(RAEB-2) by WHO 2008 classification presented a signifi-
cantly reduced TET2 expression compared to other MDS
classifications refractory anemia (RA), refractory anemia
with ringed sideroblasts (RARS), MDS with isolated del(5q)
[MDS del(5q)], and refractory cytopenia with multilineage
dysplasia (RCMD) (P = 0.04) (Fig. 1B). When patients with
MDS were stratified and grouped according to IPSS-R,
patients with MDS classified as high and very high risk pre-
sented a significantly reduced TET2 expression compared to
the group of patients including very low, low, and intermedi-
ate risk (P = 0.04) (Fig. 1C). TET2 expression was evalu-
ated at sequential samples from five patients with MDS that
progressed during the period of this study. Four of five
patients with MDS showed a marked decrease in TET2
levels after disease progression (Fig. 1D).
Low TET2 expression negatively impacts survival
outcomes in patients with MDS
By univariate analysis, clinical factors that significantly
affected both EFS and OS included WHO 2008 diagnosis
(RAEB-1/RAEB-2 vs. others, P ≤ 0.0001), IPSS-R (very
high/high risk vs. very low/low/intermediate risk,
P ≤ 0.0002). Reduced TET2 expression negatively impacted
both EFS (P ≤ 0.05) and OS (P ≤ 0.05) by univariate analy-
sis, even when tested as continuous variable or categorical
variable stratified by median or tertile. Multivariate analyses
indicated that low TET2 expression stratified by median
(P = 0.03), along with male gender (P = 0.02), and RAEB-
1/RAEB-2 WHO 2008 classification (P ≤ 0.0001) was
independently prognostic for worse OS (Table 2).
Discussion
We herein observed a significant downregulation of TET2
expression in total bone marrow cells from patients with
MDS and AML compared with cells from healthy donors;
and from patients with MDS RAEB-1/RAEB-2 by WHO
2008 or high/very high risk by IPSS-R compared to other
patients with MDS. These findings are in agreement with
Jankowska and colleagues (2), who reported a reduced
TET2 expression in CD34+ cells from 16 patients with
MDS/MPN, which was independent of the TET2 muta-
tional status. Recently, another group reported reduced
TET2 mRNA levels in bone marrow mononuclear cells
from a cohort of 32 patients with MDS compared with a
control group, and in the RAEB compared to RA/RARS
subtype, corroborating our findings (15), but the impact of
TET2 expression on MDS survival outcomes has not been
previously addressed. In the present study, we had the
opportunity to evaluate TET2 expression in sequential
bone marrow samples from five cases of low-risk MDS
that evolved to a high-risk disease. Interestingly, four of
five cases showed a reduction of TET2 expression after
disease progression; note that the patients with higher aug-
mentations in bone marrow blasts percentages presented
the highest rates of TET2 reduction. One of the patients
did not present a reduced TET2 expression at the time of
progression, which may be due to the clinical and molec-
ular heterogeneity of MDS disease, and/or due to the low
increment in bone marrow percentage at disease progres-
sion. In this sense, Zhang et al. (15) reported that high
expressions of TET2 were observed in patients with lower
percentages of bone marrow blast. In chronic myeloid leu-
kemia, Albano et al. (16) also described a downregulation
of TET2 expression during disease progression. The med-
ian of TET2 expression was significantly reduced in
patients with ≥5% bone marrow blasts (RAEB-1 and
RAEB-2) compared to the others, as observed in Fig. 1B.
However, no significant correlation was observed among
the percentage of blasts and TET2 expression values
(r = 0.21, P = 0.10; Spearman’s correlation test). The
absence of correlation may be due to the dispersion of
TET2 expression values among the group of patients with
MDS with less than 5% bone marrow blasts. Taken
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together, these data suggest that downregulation of TET2
expression in high-risk MDS and AML may be associated
with MDS progression and leukemia phenotype.
Low TET2 expression was independently prognostic for
decreased OS in our cohort of patients with MDS. The clini-
cal impact of TET2 expression on myeloid malignancies has
not been previously addressed, as discussed above. How-
ever, the clinical impact of TET2 mutations on the survival
outcome of these patients is still controversial. In MDS,
Kosminder and colleagues reported an association between
TET2 mutations and a decreased risk of progression and a
longer survival (7). Liu and colleagues reported that patients
with MDS and high 5-hmC levels had a longer OS, but no
correlation between TET2 mutations and OS was found in a
cohort of 61 patients with MDS (17). TET2 mutation had no
significant impact on prognosis when analyzed together with
other molecular mutations in a cohort of 1185 patients with
AML (18). On the other hand, the TET2 mutation negatively
impacted prognosis in patients with AML with intermediate-
risk cytogenetics (19). In patients with secondary AML
and CML, TET2 mutations showed a shorter OS (8,20).




Figure 1 Downregulation of TET2 in total bone marrow cells from patients with MDS and AML. (A) qPCR analysis of TET2 mRNA expression in
total bone marrow cells from healthy donors, and from patients with diagnosis of myelodysplastic syndromes (MDS) and acute myeloid leukemia
(AML), and from patients with MDS stratified by WHO 2008 classification (B) and IPSS-R (C). The ‘y’ axis represents the relative TET2 mRNA
expression. Horizontal lines indicate medians. The numbers of subjects studied and the P values (Mann–Whitney test) are indicated in the graph.
(D) TET2 mRNA levels in total bone marrow cells from five patients with MDS at diagnosis and at the time of disease progression; the WHO
2008 classification is indicated. Bar graph represents the mean  SD of three qPCR analyses. Abbreviation: MDS, myelodysplastic syndromes;
WHO, World Health Organization; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; del(5q), MDS with isolated del(5q);
RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blast-1; RAEB-2, refractory anemia with excess
blast-2; BM, bone marrow; IPSS-R, Revised International Prognostic Scoring System; AML with isolated del(5q), acute myeloid leukemia with iso-
lated deletion on chromosome 5q; AML–MRC, acute leukemia with myelodysplasia-related changes.
416 © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
TET2 is downregulated in myelodysplastic syndromes Scopim-Ribeiro et al.
differences in cohorts of patients studied and different meth-
odologies. Future studies including TET2 mutation analysis
by next generation sequencing, combined with TET2 expres-
sion and 5-hmc levels, including studies that take into
account the combined analyses of multiple molecular muta-
tions will be necessary to better define the impact of loss of
function of TET2 on the prognosis of the myeloid diseases.
In summary, these results suggest that defective TET2
expression plays a role in MDS pathophysiology and may
affect survival in these patients. Additional prospective stud-
ies of TET2 expression in different cohorts of patients and
different cell populations, combined with mutation analysis,
are necessary to validate our findings and may be of interest
in patients with MDS.
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